OMICS-based personalized oncology: if it is worth doing, it is worth doing well!

BMC Medicine

Daniel F Hayes¹ 

[1] Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 6312 Cancer Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0942, USA

关键词: Clinical investigation;    Tumor biomarker tests;   

Others  :  855621
DOI  :  10.1186/1741-7015-11-221

 received in 2013-09-19, accepted in 2013-09-19,  发布年份 2013

【 摘 要 】

The era of Personalized Medicine implies getting the right treatment to the right patient at the right schedule and dose at the right time. Tumor biomarker tests are keys to accomplishing this goal successfully. However, much of the translational research regarding tumor biomarker tests has been haphazard, often using data and specimen sets of convenience and ignoring many of the principles of the scientific method. In papers published simultaneously in BMC Medicine and Nature, McShane and colleagues have proposed a checklist of criteria that should be followed by investigators planning to conduct prospective clinical trials directed towards generating high levels of evidence to demonstrate whether a tumor biomarker test has clinical utility for a specific context. These criteria were generated in response to a roadmap reported by a committee convened by the U.S. Institute of Medicine for generation of omics-based biomarker tests. Taken together with several other initiatives to increase the rigor of tumor biomarker research, these criteria will increase the perception of value for tumor biomarker test research and application in the clinic.

Please see related article: http://www.biomedcentral.com/1741-7015/11/220 webcite.

【 授权许可】

   
2013 Hayes; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Schilsky RL: Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol 2009, 27:3725-3730.
• [2]Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010, 134:e48-72.
• [3]Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795.
• [4]Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
• [5]Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology/College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43.
• [6]Institute of Medicine: Evolution of Translational omics: Lessons Learned and the Path Forward. Washington, DC: The National Academies Press; 2012.
• [7]Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
• [8]McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072.
• [9]Moore HM, Kelly A, McShane LM, Vaught J: Biospecimen reporting for improved study quality (BRISQ). Clin Chim Acta 2012, 413:1305.
• [10]Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009, 11:3-14.
• [11]Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009, 101:1446-1452.
• [12]McShane L, Hayes DF: Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol 2012, 30:4223-4232.
• [13]Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ: Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013, 3:224-237.
• [14]Sargent DJ, Conley BA, Allegra C, Collette L: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005, 23:2020-2027.
• [15]Freidlin B, McShane LM, Polley MY, Korn EL: Randomized phase II trial designs with biomarkers. J Clin Oncol 2012, 30:3304-3309.
• [16]McShane LM, Cavenagh MM, Lively T, Eberhard DA, Bigbee WL, Williams MP, Mesirov JP, Polley MY, Kim KY, Tricoli JV: Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration. BMC Med 2013, 11:220.
• [17]McShane LM, Cavenagh MM, Lively T, Eberhard DA, Bigbee WL, Williams MP, Mesirov JP, Polley MY, Kim KY, Tricoli JV, et al.: Criteria for the use of omics-based predictors in clinical trials. Nature 2013, 502:317-320.
• [18]Hayes DF: Genome to bedside: Lost in translation - the importance of demonstrating analytical validity and high levels of evidence of clinical utility before adopting a tumor biomarker into routine clinical use. Breastin press
• [19]Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR: Breaking a vicious cycle. Sci Transl Med 2013, 5:196cm196.